Isolation and characterization of Candida spp. in Jordanian cancer patients: Prevalence, pathogenic determinants, and antifungal sensitivity

Japanese Journal of Infectious Diseases

Volumn 57, Issue 6, 2004, Pages 279-284

  Al Abeid, Hanan M ^a   Abu Elteen, Khaled H ^a   Elkarmi, Ali Z ^a   Hamad, Mawieh A ^a  

^a HASHEMITE UNIVERSITY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FUNGAL PROTEIN; MICONAZOLE; NYSTATIN; PHOSPHOLIPASE; PROTEINASE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER PATIENT; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HEALTH CARE PERSONNEL; HOSPITAL PATIENT; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; NONHUMAN; OUTPATIENT; PATHOGENESIS; PREVALENCE; PROTEIN SECRETION; SPECIES DIFFERENCE; THRUSH; YEAST CELL;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DEVELOPING COUNTRIES; FEMALE; HUMANS; JORDAN; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; VIRULENCE;

EID: 13844319170     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Akpan, A. and Morgan, R. (2002): Oral candidiasis: a review. Postgrad. Med. J., 78, 455-459.
2. Manning, D. J., Coughlin, R. P. and Poskit, E. M. (1985): Candida in mouth or on dummy? Arch. Dis. Child., 60, 381-382.
3. Berdicevsky, I., Ben-Aryeh, H., Sazargel, R. and Gutman, D. (1980): Oral Candida in children. Oral Surg. Oral Med. Oral Pathol., 57, 37-40.
4. Lucas, V. S. (1993): Association of psychotropic drugs, prevalence of denture-related stomatitis and oral candidosis. Community Dent. Oral Epidemiol., 21, 313-316.
5. Abu-Elteen, K. H. and Abu-Alteen, R. M. (1998): The prevalence of Candida albicans populations in the mouths of complete denture wearers. New Microbiol., 21, 41-48.
6. Holbrook, W. P. and Hjorleifsdottir, D. V. (1986): Occurrence of oral Candida albicans and other yeast-like fungi in edentulous patients in geriatric units in Iceland. Gerodontics, 2, 153-156.
7. Oppenheim, B. A. (1998): The changing pattern of infection in neutropenic patients. J. Antimicrob. Chemother., 41, 7-11.
8. Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L. and Walsh, T. J. (2000): Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus infected children: in vitro and clinical correlations. J. Clin. Microbiol., 38, 1563-1568.
9. Abu-Elteen, K. H., Elkarmi, A. Z. and Hamad, M. (2001): Characterization of phenotype-based pathogenic determinants of various Candida albicans strains in Jordan. Jpn. J. Infect. Dis., 54, 229-236.
10. Kuriyama, T., Williams, D. W. and Lewis, M. A. (2003): In vitro secreted aspartyl proteinase activity of Candida albicans isolated from oral diseases and healthy oral cavities. Oral Microbiol. Immunol., 18, 405-407.
11. Ghannoum, M. A. (2000): Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev., 13, 122-143.
12. Ibrahim, A. S., Mirbod, F., Filter, S. G., Banno, Y., Cole, G. T., Kitajima, Y., Edwards, J. E., Nozawa, Y. and Ghannoum, M. A. (1995): Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect. Immun., 63, 1993-1998.
13. Odds, F. C. (1994): Candida species and virulence. ASM News, 60, 313-318.
14. Budtz-Jorgensen, E. (1990): Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. Acta Odontol. Scand., 48, 61-69.
15. Ito-Kuwa, S., Nakamura, Y., Aoki, S., Nakamura, K., Vidotto, V. and Sinicco, A. (1997): Oral yeasts isolated from normal subjects in three successive trials. Jpn. J. Oral Biol., 39, 100-106.
16. Abu-Elteen, K. H. (2000): Candida albicans strain differentiation in complete denture wearers. New Microbiol., 23, 329-337.
17. Odds, F. C. and Bernaerts, R. (1994): CHROMagar Candida a new differential isolation medium for presumptive identification of clinically important Candida species. J. Clin. Microbiol., 32, 1923-1929.
18. Staib, F. (1965): Serum- proteins as nitrogen source for yeast-like fungi. Sabouraudia, 4, 187-193.
19. Abu-Elteen, K. H. (2000): Effects of date extract on adhesion of Candida species to human buccal epithelial cells in vitro. J. Oral Pathol. Med., 29, 200-205.
20. National Committee for Clinical Laboratory Standards (1997): Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Leung, W. K., Dassanayake, R. S., Yau, J., Jin, L. J., Yam, W. and Samaranayake, L. P. (2000): Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic, nasopharyngeal carcinoma survivors. J. Clin. Microbiol., 38, 2219-2226.
22. Redding, S. W., Zellars, R. C., Kirkpatrick, W. R., McAtee, R. K., Caceres, M. A., Fothergill, A. W., Lopez-Ribot, J. L., Bailey, C. W., Rinaldi, M. G. and Patterson, T. F. (1999): Epidemiology of oropharyngeal. Candida colonization and infection in patients receiving radiation for head and neck cancer. J. Clin. Microbiol., 37, 3896-3900.
23. Ninane, J. A. (1994): Multicenter study of fluconazole versus oral polyenes in the prevention of fungal infection in children with haematological or oncological malignancies. Multicenter study group. Eur. J. Clin. Microbiol. Infect. Dis., 13, 330-337.
24. Safdar, A., Chaturvedi, V., Cross, E. W., Park, S., Bernard, E. M., Armstrong, D. and Perlin, D. (2001): Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob. Agents Chemother., 45, 2129-2133.
25. Anaissie, E. (1992): Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis., 14, 43-53.
26. Wingard, J. (1995): Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis., 20, 115-125.
27. Bodey, G., Mardani, M., Hanna, H., Boktour, M., Abbas, J., Girgawy, E., Hachem, R., Kontoyiannis, D. and Raad, I. (2002): The epidemiology of Candida glabrata fungemia in immuno-compromised patients with cancer. Am. J. Med., 112, 380-385.
28. Abi-Said, D., Anaissie, E., Uzum, O., Raad, I., Pinzcowski, H. and Vartivarian, S. (1997): The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 24, 1122-1128.
29. Schaller, M., Mailhammer, R., Grass, G., Sander, C., Hube, B. and Korting, H. (2002): Infection of human oral epithelial with Candida species induces cytokine expression correlated to the degree of virulence. J. Invest. Dermatol., 118, 652-657.
30. Fidel, P., Vazquez, J. and Sobel, J. (1999): Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to Candida albicans. Clin. Microbiol. Rev., 12, 80-96.
31. Hube, B. (2000): Extracellular proteinases of human pathogenic fungi. p. 126-137. In Ernst J. F. and Schmidt, A. (eds.), Dimorphism in Human Pathogenic and Apathogenic Yeasts. vol 5. Karger, Basel.
32. Pfaller, M. A., Jones, R. N., Doem, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J. and the SENTRY Participant Group (2000): Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother., 44, 747-751.
33. Pfaller, M. A., Bale, M., Buschelman, B., Lancaster, M., Espinel-Ingroff, A., Rex, J. H., Rinaldi, M. G., Cooper, C. R. and McGinnis, M. R. (1995): Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole and flucytosine. J. Clin. Microbiol., 33, 1104-1107.
34. Espinel-Ingroff, A., Pfaller, M., Messer, S. A., Knapp, C. C., Killian, S., Norris, H. A. and Ghannoum, M. A. (1999): Multicenter comparison of the sensititre yeast one colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J. Clin. Microbiol., 37, 591-595.
35. Araj, G. F., Daher, N. K. and Tabbarah, Z. A. (1998): Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center. Int. J. Antimicrob. Agent, 10, 291-296.
36. Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A. and the SENTRY Participation Group (2001): International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial survillance program. J. Clin. Microbiol., 39, 3254-3259.
37. Bille, J., Glauser, M. P. and the Fluconazole Global Susceptibility Group (1997): Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Eur. J. Clin. Microbiol. Infect. Dis., 16, 924-927.